Automated Packaging Autobag Bagger, Model HS-100 EXCEL One (1) used Automated Packaging System Autobag bagger, model HS-100 EXCEL, speeds up to 24 bags/minute, 10.5' wide x 22' long max bag size, with PI-4000 Autolabel printer and 12' wide x 7' long inclinded discharge belt conveyor, Autobag part# 591000A1, serial# 01-08XL-5116. Pre-Owned Autobag HS-100 Excel Bagger with PI-4000 Thermal Transfer Bag Printer. SOLD - Used HS-100XL AutoBagger with PI-4000 Printer. Each payday it will save you time by generating automated Hs 100 Excel Bagging Machine Manual reports for your employees. 
Oligodendrocytes, myelin-producing cells In 2011, Paul Tesar, a professor at Case Western Reserve School of Medicine, worked with collaborators to of producing massive numbers of mouse stem cells that are capable of turning into oligodendrocytes, the cells that produce myelin, the protective coating on nerve cells. One thing you can do with such a technique, assuming you can do the same thing with human cells, is to use biochemical legerdemain to restore the myelin lost in multiple sclerosis, cerebral palsy and other disorders. But cell replacement therapies are still a work in progress–and may continue to be so for a long time. A nearer term project for these cell populations is to test known drugs to see whether they might succeed in turning stem cells milling around the nervous system into myelin-producing oligodendrocytes. Tesar and team screened 727 drugs that had been safely used in patients.
Among them they found seven that could do the job of making the switch from stem cell to oligodendrocyte. The team decided to focus on the top two, both already approved by the FDA for use on the skin. There was an antifungal (miconazole) and a steroid (clobetasol). Both drugs, when administered by injection, substantially increased the production of myelin-producing cells and myelin itself in mouse models of multiple sclerosis when compared to a rodent control group that received placebos. The two compounds also reduced the severity of the MS-like disease model in the animals–and the drugs even promoted the transformation of human stem cells in culture into oligodendrocytes. April 20 in Nature.
There has been more progress in developing drugs for multiple sclerosis than for other neurodegenerative diseases like Alzheimer’s and Parkinson’s. MS, which affects 2 million people worldwide and 450,000 in the U.S, results in aberrant nerve signaling from the myelin damage that can affect the ability to walk or even see. The MS field already has some drugs that can actually modify the progression of the disease by quelling the body’s auto-immune reaction against its own myelin. But there is also a need to repair damage to the myelin itself. Dennis Bourdette, who chairs the department of neurology at Oregon State Health University and directs the university’s Multiple Sclerosis and Neuroimmunology Center, puts it this way: All medications currently used to treat multiple sclerosis (MS) are anti-inflammatory. They control the abnormal immune response that attacks and destroys myelin in the brain and spinal cord.
However they do not repair damage that has already occurred. 
The two drugs studied by Najm and colleagues [including Paul Tesar] are fundamentally different. They stimulate the cells, called oligodendrocytes, that make myelin and successfully stimulated remyelination in two animal models of MS. These drugs or derivatives of these drugs have the potential to be a new approach to treating MS and would be used in combination with current anti-inflammatory therapies.
Automated Packaging Autobag Bagger, Model HS-100 EXCEL One (1) used Automated Packaging System Autobag bagger, model HS-100 EXCEL, speeds up to 24 bags/minute, 10.5' wide x 22' long max bag size, with PI-4000 Autolabel printer and 12' wide x 7' long inclinded discharge belt conveyor, Autobag part# 591000A1, serial# 01-08XL-5116. Pre-Owned Autobag HS-100 Excel Bagger with PI-4000 Thermal Transfer Bag Printer. SOLD - Used HS-100XL AutoBagger with PI-4000 Printer. Each payday it will save you time by generating automated Hs 100 Excel Bagging Machine Manual reports for your employees.
Oligodendrocytes, myelin-producing cells In 2011, Paul Tesar, a professor at Case Western Reserve School of Medicine, worked with collaborators to of producing massive numbers of mouse stem cells that are capable of turning into oligodendrocytes, the cells that produce myelin, the protective coating on nerve cells. One thing you can do with such a technique, assuming you can do the same thing with human cells, is to use biochemical legerdemain to restore the myelin lost in multiple sclerosis, cerebral palsy and other disorders. But cell replacement therapies are still a work in progress–and may continue to be so for a long time. A nearer term project for these cell populations is to test known drugs to see whether they might succeed in turning stem cells milling around the nervous system into myelin-producing oligodendrocytes. Tesar and team screened 727 drugs that had been safely used in patients.
Among them they found seven that could do the job of making the switch from stem cell to oligodendrocyte. The team decided to focus on the top two, both already approved by the FDA for use on the skin. There was an antifungal (miconazole) and a steroid (clobetasol). Both drugs, when administered by injection, substantially increased the production of myelin-producing cells and myelin itself in mouse models of multiple sclerosis when compared to a rodent control group that received placebos. The two compounds also reduced the severity of the MS-like disease model in the animals–and the drugs even promoted the transformation of human stem cells in culture into oligodendrocytes. April 20 in Nature.
There has been more progress in developing drugs for multiple sclerosis than for other neurodegenerative diseases like Alzheimer’s and Parkinson’s. MS, which affects 2 million people worldwide and 450,000 in the U.S, results in aberrant nerve signaling from the myelin damage that can affect the ability to walk or even see. The MS field already has some drugs that can actually modify the progression of the disease by quelling the body’s auto-immune reaction against its own myelin. But there is also a need to repair damage to the myelin itself. Dennis Bourdette, who chairs the department of neurology at Oregon State Health University and directs the university’s Multiple Sclerosis and Neuroimmunology Center, puts it this way: All medications currently used to treat multiple sclerosis (MS) are anti-inflammatory. They control the abnormal immune response that attacks and destroys myelin in the brain and spinal cord.
However they do not repair damage that has already occurred. The two drugs studied by Najm and colleagues [including Paul Tesar] are fundamentally different. They stimulate the cells, called oligodendrocytes, that make myelin and successfully stimulated remyelination in two animal models of MS. These drugs or derivatives of these drugs have the potential to be a new approach to treating MS and would be used in combination with current anti-inflammatory therapies.
Automated Packaging Autobag Bagger, Model HS-100 EXCEL One (1) used Automated Packaging System Autobag bagger, model HS-100 EXCEL, speeds up to 24 bags/minute, 10.5' wide x 22' long max bag size, with PI-4000 Autolabel printer and 12' wide x 7' long inclinded discharge belt conveyor, Autobag part# 591000A1, serial# 01-08XL-5116. Pre-Owned Autobag HS-100 Excel Bagger with PI-4000 Thermal Transfer Bag Printer. SOLD - Used HS-100XL AutoBagger with PI-4000 Printer. Each payday it will save you time by generating automated Hs 100 Excel Bagging Machine Manual reports for your employees.
Oligodendrocytes, myelin-producing cells In 2011, Paul Tesar, a professor at Case Western Reserve School of Medicine, worked with collaborators to of producing massive numbers of mouse stem cells that are capable of turning into oligodendrocytes, the cells that produce myelin, the protective coating on nerve cells. One thing you can do with such a technique, assuming you can do the same thing with human cells, is to use biochemical legerdemain to restore the myelin lost in multiple sclerosis, cerebral palsy and other disorders. But cell replacement therapies are still a work in progress–and may continue to be so for a long time. A nearer term project for these cell populations is to test known drugs to see whether they might succeed in turning stem cells milling around the nervous system into myelin-producing oligodendrocytes. Tesar and team screened 727 drugs that had been safely used in patients.
Among them they found seven that could do the job of making the switch from stem cell to oligodendrocyte. The team decided to focus on the top two, both already approved by the FDA for use on the skin. There was an antifungal (miconazole) and a steroid (clobetasol). Both drugs, when administered by injection, substantially increased the production of myelin-producing cells and myelin itself in mouse models of multiple sclerosis when compared to a rodent control group that received placebos. The two compounds also reduced the severity of the MS-like disease model in the animals–and the drugs even promoted the transformation of human stem cells in culture into oligodendrocytes. April 20 in Nature.
There has been more progress in developing drugs for multiple sclerosis than for other neurodegenerative diseases like Alzheimer’s and Parkinson’s. MS, which affects 2 million people worldwide and 450,000 in the U.S, results in aberrant nerve signaling from the myelin damage that can affect the ability to walk or even see. The MS field already has some drugs that can actually modify the progression of the disease by quelling the body’s auto-immune reaction against its own myelin. But there is also a need to repair damage to the myelin itself. Dennis Bourdette, who chairs the department of neurology at Oregon State Health University and directs the university’s Multiple Sclerosis and Neuroimmunology Center, puts it this way: All medications currently used to treat multiple sclerosis (MS) are anti-inflammatory. They control the abnormal immune response that attacks and destroys myelin in the brain and spinal cord.
However they do not repair damage that has already occurred. The two drugs studied by Najm and colleagues [including Paul Tesar] are fundamentally different. They stimulate the cells, called oligodendrocytes, that make myelin and successfully stimulated remyelination in two animal models of MS. These drugs or derivatives of these drugs have the potential to be a new approach to treating MS and would be used in combination with current anti-inflammatory therapies.